BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 815858)

  • 1. Combination chemotherapy with CCNU (NSC-79037),hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in advanced bronchogenic carcinoma.
    DiBella NJ; Nelson RA; Norgard MJ
    Oncology; 1975; 32(2):82-5. PubMed ID: 815858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
    Wilson WL; Andrews NC; Frelick RW; Nealon TF; Bick RL; Adams T
    Cancer Treat Rep; 1976 Mar; 60(3):269-71. PubMed ID: 816467
    [No Abstract]   [Full Text] [Related]  

  • 3. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
    Mintz U; Bitran JD; Cooksey JA; Desser RK; DeMeester TR; Golomb HM
    Cancer Treat Rep; 1978 Apr; 62(4):567-9. PubMed ID: 77725
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
    Stolinsky DC; Bull FE; Pajak TF; Bateman JR
    Oncology; 1975; 31(5-6):288-92. PubMed ID: 174040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCNU-adriamycin therapy in bronchogenic carcinoma.
    Trowbridge RC; Kennedy BJ; Vosika GJ
    Cancer; 1978 May; 41(5):1704-9. PubMed ID: 206337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study.
    Green M; Horton C; Spaulding M; Silver RT; Berenberg J; Kennedy BJ; Pajak TF; Comis R
    J Clin Oncol; 1983 Sep; 1(9):559-65. PubMed ID: 6422007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma.
    McMahon LJ; Jones SE; Durie BG; Salmon SE
    Cancer Lett; 1975 Nov; 1(2):97-102. PubMed ID: 65213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine.
    Chahinian PA; Arnold DJ; Cohen JM; Purpora DP; Jaffrey IS; Teirstein AS; Kirschner PA; Holland JF
    JAMA; 1977 May; 237(22):2392-6. PubMed ID: 576939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CCNU (NSC-79037) on bronchogenic carcinoma.
    Takita H; Brugarolas A
    J Natl Cancer Inst; 1973 Jan; 50(1):49-53. PubMed ID: 4348225
    [No Abstract]   [Full Text] [Related]  

  • 10. A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
    Alberto P; Barrelet L; Chapuis B; Garcia B
    Eur J Cancer (1965); 1975 Nov; 11(11):795-9. PubMed ID: 767111
    [No Abstract]   [Full Text] [Related]  

  • 11. Nitrosourea combinations in lung cancer.
    Livingston RB
    Cancer Treat Rep; 1976 Jun; 60(6):757-760. PubMed ID: 182365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized pilot study comparing two regimens in the treatment of squamous cell carcinoma.
    Moseley HS; Sasaki T; McConnell DB; Merhoff GC; Wilson WL; Grage TB; Wiess AJ; Fletcher WS
    J Surg Oncol; 1976; 8(1):35-42. PubMed ID: 55523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatment of inoperable squamous and large cell carcinoma of the lung.
    Edmonson JH; Lagakos S; Stolbach L; Perlia CP; Bennett JM; Mansour EG; Horton J; Regelson W; Cummings FJ; Israel L; Brodsky I; Shnider BI; Creech R; Carbone PP
    Cancer Treat Rep; 1976 May; 60(5):625-7. PubMed ID: 186183
    [No Abstract]   [Full Text] [Related]  

  • 14. Methyl-CCNU, alone and in combination with vincristine, or vincristine and methotrexate, in advanced bronchogenic carcinoma.
    Richards F; Cooper MR; Muss HB; White DR; Spurr CL
    Cancer; 1976 Sep; 38(3):1077-82. PubMed ID: 953956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
    Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
    Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of the effect of methyl-CCNU (NSC-95441) on bronchogenic carcinoma.
    Takita H; Brugarolas A; Mittelman A; Vincent R
    Cancer Chemother Rep 3; 1973 Mar; 4(2):257-9. PubMed ID: 4125743
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung.
    Weiss AJ; Wilson WL
    Cancer Chemother Rep; 1971 Jun; 55(3):299-302. PubMed ID: 5115850
    [No Abstract]   [Full Text] [Related]  

  • 19. Superior vena caval obstruction due to small-cell anaplastic lung carcinoma. Response to chemotherapy.
    Kane RC; Cohen MH
    JAMA; 1976 Apr; 235(16):1717-8. PubMed ID: 176480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small cell bronchogenic carcinoma. A prolonged remission following chemotherapy.
    Cohen MH
    JAMA; 1977 Jun; 237(23):2528. PubMed ID: 576972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.